Subscribe to Print Edition | Thu., April 10, 2008 Nisan 5, 5768 | | Israel Time: 02:02 (EST+7) web haaretz.com   Back to Homepage Rosner's Domain Diplomacy Defense Jewish World Opinion National Print Edition Advertising Books Arts & Leisure Business Real Estate Easy Start Travel Week's End Anglo File

Rosetta submits first cancer diagnostic tool for approval By Yoram Gabison Tags: Israel, Economy Rosetta Genomics and Columbia University Medical Center announced last week that they have submitted the first cancer diagnostic test based on Rosetta Genomics proprietary microRNA technology for approval to the New York State Department of Health clinic. The test is designed to differentiate squamous (scale-like) from non-squamous non-small cell lung cancer (NSCLC), classifying squamous cell carcinoma of the lung with sensitivity of 96% (correct positive results) and specificity of 90% (correct negative results). Accurate diagnosis is important for guiding treatment for non-squamous NSCLC with the drug Avastin. In keeping with FDA instructions, Avastin carries a warning about potential severe or fatal hemorrhage in patients with squamous NSCLC histology. Ronen Tamir, Rosetta Genomics' Marketing and Communications VP, noted that U.S. laboratory standards program (CLIA) requires that the instrument meet certain standards of accuracy and reliability. New York, he said, is the only state in which laboratory testing approval is issued by the State Health Department, and recognized by all U.S.states. This means that with New York Health Department approval, the technological benefits will be available to oncologists throughout the U.S., through Columbia University Medical Center's molecular pathology laboratory, which developed the instrument. Advertisement Tamir said that the NY Health Department's process is expected to continue over a period of up to six months. The product will be marketed through the medical center, which has paid Rosetta royalties for the use of its microRNA technology. Tamir estimates that the cost of the test will be about $6,000. About 60,000 persons become ill with lung cancer every year in the U.S. Rosetta developed the diagnostic technology based on microRNA, small molecules which are crucial to the regulation of protein activities in the body. Because many diseases are caused by disturbances in the regulation of protein activity, identification of the microRNAs is expected to be instrumental in the diagnosis of many diseases. Tamir said that the importance of diagnostics in the development of new pharmaceuticals increases as drugs become more specialized. The firm intends to submit two additional diagnostic tools for approval later this year. One test is designed to differentiate mesothelioma, an asbestos-associated cancer that develops in the pleura, from other cancers that spread to the pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary (CUP) origin. Rosetta was floated on Nasdaq in February 2007 at $7 per share, and is now traded at $4.95 per share, reflecting a market cap of $59 million. Bookmark to del.icio.us   Carter's contacts Report: Ex-U.S. president Carter to meet with Hamas leader in Syria. Warning shouts Officer: Palestinians warned Israelis of terrorist infiltration.

Today Online Israel to deny UN official entry for comparing country to Nazis Responses: 330 Rosner's Guest: Enough with occupation guilt, Gaza is not Auschwitz Responses: 61 State Prosecutor: New Katsav indictment may include rape Responses: 17 Alexander Yakobson: Israel is most successful integration of modern times Responses: 26 IDF begins collecting weapons from West Bank settlements Responses: 44 More Headlines 23:55 Local security officer: Palestinians warned of infiltration 00:59 2 Israeli civilians killed in attack by Gaza infiltrators 21:49 Israel: Hamas responsible for Gaza attack, will pay the price 01:52 Druze elite-unit son buried with honors, but not in military cemetery 00:53 PA police and escaped Fatah militants clash in Nablus 20:48 Report: Ex-U.S. president Carter to meet with Hamas leader in Syria 21:55 Vatican cardinal: Jews too 'emotional' over Good Friday prayer 21:27 Polish PM: Iran's comments on Israel annuls right to place in int'l community 14:41 Murdoch, Blair, Gorbachev to attend Israel's 60th celebrations 00:08 Gunfight erupts on central Tel Aviv street during jewel heist 20:35 Unionized J'lem teens declare labor dispute with employer 19:08 Egyptian troops go on alert, fear new Hamas bid to breach Gaza border 16:18 Judge allows Mosley Nazi role-playing orgy video to go on Web Previous Editions Select Day 09 apr 08 apr 07 apr 06 apr 04 apr 03 apr 02 apr 01 apr 31 mar 30 mar 28 mar 27 mar

Special Offers Advertisement Learn Hebrew online with Israel's best teachers Sign up for a trial lesson today Behind the Z Word Scholarly essays, commentary, podcasts, blogs and much more. NEW! Dan Boutique Jerusalem Hotel Hip Dan Hotel in Jerusalem. Attractive Introductory Rates Pardes Institute Summer Sessions Study Jewish texts and issues in Jerusalem, Co-ed, All Levels FAREWELL ISRAEL New Film The Coming War for Islamic Revival - View Movie Trailer Free the Palestinians from: Corrupt Kleptocracy, Tyrannical Theocracy, Abysmal Anarchy Fattal Hotel Chain Perfectly located hotels on best resorts of Israel. ISRAEL BONDS Build Israel Israel bonds - a multi-purpose way to celebrate Israel's 60th Eldan Rent a Car Israel's leading car rental company offers you a 20% discount on all online reservations Junkyard Junk a car - get free towing nationwide and a tax-deductible receipt

Home | TV | Print Edition | Diplomacy | Opinion | Arts & Leisure | Sports | Jewish World | Underground | Site rules |

Haaretz.com, the online edition of Haaretz Newspaper in Israel, offers real-time breaking news, opinions and analysis from Israel and the Middle East. Haaretz.com provides extensive and in-depth coverage of Israel, the Jewish World and the Middle East, including defense, diplomacy, the Arab-Israeli conflict, the peace process, Israeli politics, Jerusalem affairs, international relations, Iran, Iraq, Syria, Lebanon, the Palestinian Authority, the West Bank and the Gaza Strip, the Israeli business world and Jewish life in Israel and the Diaspora.

© Copyright  Haaretz. All rights reserved